Nanjing Vcare Won the Title of "Excellent Strategic Cooperation Supplier of Kelun Pharmaceutical in 2021"

2022-06-28

At the end of June 2022, Nanjing Vcare PharmaTech Co., Ltd. ("Nanjing Vcare") won the honorary title of "Excellent Strategic Cooperation Supplier" awarded by Sichuan Kelun Pharmaceutical Co., Ltd. ("Kelun Pharmaceutical").

 

Since 2013, Vcare PharmaTech has maintained a positive, stable and friendly cooperative relationship with Kelun Pharmaceutical in the field of drug research and development service support. After ten years, it has now become an important strategic partner of Kelun Pharmaceutical. Especially since 2021, under the severe situation, the two sides have supported each other and overcome difficulties together. Nanjing Vcare has always put the needs of its partners first and adhered to high standards in aspects such as product quality, product supply and product service, striving to achieve a win-win situation with its partners.
Up to now, Nanjing Vcare has given full play to the advantages of its whole-industrial-chain research and development services and has successively cooperated with Kelun Pharmaceutical on more than 10 products and projects, including Empagliflozin, Relugolix, Mirogabalin, Eltrombopag, Baricitinib, Ixazomib​​​​​​​ and so on. The acquisition of this honor is not only the recognition of Nanjing Vcare's comprehensive strength, product and service quality and corporate brand by its partners, but also the result of the company's hard work along the way.
An honor is a kind of affirmation and also a responsibility. In the future, Nanjing Vcare will move forward with this honor, adhere to innovation-driven development, continuously enhance its core competitiveness and earnestly provide partners with higher-quality products and services.

Prev

Nanjing Vcare Helps Hainan Hualon Pharmaceutical to Pass the Consistency Evaluation of Aztreonam for Injection

Next

Jiangsu Vcare Wholly-owned Subsidiary Nanjing Vcare Successfully Acquired Hubei Tianshu Pharmaceutical